利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

357 条记录 (耗时 0.013 秒)

    HLA-A *01-binding T-cell epitope of WT1
    61.
    发明公开
    HLA-A *01-binding T-cell epitope of WT1 审中-公开
    HLA-A * 01结合T-Zell-Epitop von WT1

    公开(公告)号：EP1657250A1

    公开(公告)日：2006-05-17

    申请号：EP04026827.8

    申请日：2004-11-11

    申请人： Charité - Universitätsmedizin Berlin

    发明人： Scheibenbogen, Carmen ,  Asemissen, Anne Marie ,  Stevanovic, Stefan ,  Keilholz, Ulrich

    IPC分类号： C07K14/47 ,  A61K39/00 ,  C07K7/04 ,  G01N33/574 ,  C12Q1/68

    CPC分类号： C07K14/4748 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/57426

    摘要： The present invention refers to an immunogenic HLA-A*01-binding T-cell epitope of the Wilms' tumour 1 protein (WT1) and its utility as a target in immunotherapy. In more detail, the invention refers to a polypeptide comprising an amino acid sequence as depicted in SEQ ID NO: 1, to an antibody directed to said polypeptide, to a polynucleotide encoding said amino acid sequence and to a polynucleotide which is complementary to said polynucleotide. The invention further refers to pharmaceutical compositions and in vitro applications.

    摘要翻译： 本发明涉及Wilms肿瘤1蛋白（WT1）的免疫原性HLA-A * 01结合T细胞表位及其在免疫治疗中的用途。 更详细地，本发明涉及包含SEQ ID NO：1所示氨基酸序列，针对所述多肽的抗体，编码所述氨基酸序列的多核苷酸和与所述多核苷酸互补的多核苷酸的多肽 。 本发明还涉及药物组合物和体外应用。

    CFTR MODULATORS FOR THE TREATMENT OF VASCULAR DISEASE
    67.
    发明公开
    CFTR MODULATORS FOR THE TREATMENT OF VASCULAR DISEASE 审中-公开

    公开(公告)号：EP4245302A1

    公开(公告)日：2023-09-20

    申请号：EP22162072.7

    申请日：2022-03-15

    申请人： Charité - Universitätsmedizin Berlin

    发明人： Kübler, Wolfgang ,  Simmons, Szandor ,  Asmus, Erik ,  Szulcek, Robert ,  Preißner, Robert

    IPC分类号： A61K31/404 ,  A61K31/443 ,  A61K31/47 ,  A61P7/02 ,  A61K31/4439

    摘要： The invention relates to the field of pharmaceutical compositions and the treatment and/or prevention of medical conditions comprising thrombosis, or atherosclerosis associated with pathological thrombocyte activation. The invention further relates to a cystic fibrosis transmembrane conductance regulator (CFTR) modulator for use in the treatment and/or prevention of a medical condition comprising thrombosis, or a medical condition comprising atherosclerosis and pathological thrombocyte activation, in a human subject. The invention further relates to the medical use and corresponding therapeutic methods of administering a CFTR modulator, such as ivacaftor, in the treatment and/or prevention of a medical condition pathological thrombocyte activation, adhesion and/or aggregation. In further aspects, the invention relates to a pharmaceutical composition comprising a CFTR modulator, such as ivacaftor.